Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication

Haematologica

Volumn 88, Issue 6, 2003, Pages 637-645

  Muñoz, Luz ^b   Aventín, Ana ^b   Villamor, Neus ^b   Juncà, Jordi ^b   Acebedo, Gemma ^b   Domingo, Alicia ^b   Rozman, María ^b   Torres, J Pio ^b   Tormo, Mar ^b   Nomdedéu, Josep F ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b NONE

Author keywords

Acute myeloid leukemia; FLT3 internal tandem duplication; Immunophenotype; Karyotype; Minimal residual disease

Indexed keywords

CD11B ANTIGEN; CD34 ANTIGEN; CD36 ANTIGEN; CELL MARKER; FLT3 LIGAND; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER RECURRENCE; CLONE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE DUPLICATION; GENETIC STABILITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MONOCYTE; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; SURVIVAL RATE; TANDEM REPEAT; TUMOR DIFFERENTIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIGENS, CD; CYTOGENETIC ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 10744230731     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lowenberg B, Touw I. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-92.
2. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
3. Agnes F, Shamoon B, Dina C, Rosnet O, Birnbaum D, Galibert F. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene 1994;145:283-8.
4. Lyman SD, James L, Vanden Bos T, De Vries P, Brasel K, Gliniak B, et al. Molecular cloning of a ligand for the flt3/fltk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 1993;75:1157-67.
5. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995;23:1121-7.
6. Small D, Leverstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-I, the human homolog of flk-2/flt-3 is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994;91:459-62.
7. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996;88:3383-90.
8. Hannum JF, Culpeper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994;385:643-8.
9. Meierhoff G, Dehmel U, Gruss H-J, Rosnet O, Birnbaum D, Quentmeier H, et al. Expression for FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 1995;9:1368-72.
10. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996;10:588-99.
11. Dehmel U, Zaborski M, Meierhoff G, Rosnet O, Ludwing WD, Quentmeier H, et al. Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia 1996;10:261-70.
12. Dehmel U, Quentmeier H, Drexler HG. Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines. Leukemia 1996;10:271-8.
13. Lisovsky M, Estrov X, Zhang X, Consoli U, Sanchez-Wlliams G, Snell V, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996;88:3987-97.
14. Nakao M, Yokota S, Iwai T, Kanebo H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;19:1911-8.
15. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minimi S, Miyawaki S, et al. Prognostic implications of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999;93:3074-80.
16. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11:1605-9.
17. Rombouts WJC, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000;14:675-83.
18. Kottaridis P, Gale RE, Frew ME, Harrison G, Langabeeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-9.
19. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgruoups with poor prognosis. Blood 2002;99:4326-35.
20. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233-9.
21. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
22. Moreno I, Martín G, Bolufer P, Barragán E, Rueda E, Román J et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica 2003;88:19-24.
23. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-39.
24. Horiike S, Yakota S, Nakao M, Iwai T, Sasai T, Kanebo H, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 1997;11:1442-6.
25. Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, et al, and the Leukemia Study Group of the Ministry of Health and Welfare. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia 1997;11:1447-52.
26. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Kuo MC, et al. Increased frequency and mutant levels of internal tandem duplication of FLT3 with changes of mutation patterns in 104 adult patients with relapsed acute myeloid leukemia. 7th Annual Meeting of the European Hematology Association. (Abstract) Florence, 2002.
27. Kelly LM, Liu QL, Kutok JL, Williams IF, Boulton CL, Gilliland DG. FLT3 internal duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a bone marrow transplant model. Blood 2002;99:310-8.
28. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002;99:8283-8.
29. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British cooperative group. Ann Intern Med 1985;103:620-6.
30. Cheson BD, Cassilteth PA, Head DR, Schiffer CA, Bennet JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-9.
31. ISCN (1995) An International System for Human Cytogenetic Nomenclature. Mitelman F, editor. Basel; Karger.
32. Bene MC, Castoldi G, Knapp W, Ludwing WD, Matutes E, Orfao A, et al. European Group for the immunological classification of acute leukemias: proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783-6.
33. Muñoz L, López O, Martino R, Brunet S, Bellido M, Sierra J, et al. Minimal residual disease detection with immunophenotype and RT-PCR in Philadelphia positive acute lymphoblastic leukemia. Hematologica 2000;85:40-6.
34. + lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia. Cytometry 1999;38:70-5.
35. San Miguel JF, Martinez A, Macedo A, Vidriales ME, López-Berges C, González M, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90:2465-70.
36. Muñoz L, Nomdedéu JF, Villamor N, Guardia R, Colomer D, Ribera JM, et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003;17:76-82.
37. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001;97:3589-95.
38. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002;21:2555-63.
39. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 2000;14:1766-76.
40. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nature Rev Cancer 2002;12:351-60.
41. Byrd JC, Mrózek K, Dodge R, Carroll A, Edwards C, Arthur D et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CAL-GB 8461). Blood 2002;13:4325-36.